The Online Investor
Drugs & Pharmaceuticals M&A image Drugs & Pharmaceuticals M&A » By The Online Investor Staff, updated Sat., Mar. 25, 1:19 PM Recent mergers and acquisitions in the Drugs & Pharmaceuticals M&A category.

Slide #24. Horizon Pharma, Inc. Vidara Therapeutics International Ltd.

Acquirer: Horizon Pharma, Inc. (NASDAQ:HZNP)
Acquiree: Vidara Therapeutics International Ltd.
Details: Horizon Pharma, Inc. (NASDAQ: HZNP) and Vidara Therapeutics International Ltd. (Vidara) today announced they have entered into a definitive agreement under which Horizon Pharma will acquire Vidara through a reverse merger for stock and cash valued at approximately $660 million. Horizon Pharma plc will be the name of the resulting company. Horizon Pharma plc will be organized under the laws of Ireland with a portfolio of four products marketed primarily in the United States. The proposed transaction has been unanimously approved by both companies' boards of directors. Pursuant to the agreement, Vidara will combine with Horizon Pharma, Inc. with approximately 74 percent of Horizon Pharma plc's ordinary shares to be exchanged for Horizon Pharma, Inc.'s common shares, with Horizon surviving the merger. The shareholders of Vidara will retain approximately 26 percent of Horizon Pharma plc and receive $200 million in cash, subject to certain adjustments.

Horizon Therapeutics is focused on researching, developing and commercializing medicines that address the needs for people with rare and rheumatic diseases. Co. has two segments, the orphan segment and the inflammation segment. The Orphan segment includes: TEPEZZA, which is indicated for the treatment of thyroid eye diseas; KRYSTEXXA, which is indicated for the treatment of uncontrolled gout; and PROCYSBI, which is indicated for nephropathic cystinosis. The Inflammation segment includes: PENNSAID 2% w/w, which is indicated for the treatment of pain of osteoarthritis (OA), of the knee(s); and DUEXIS, which is indicated for the relief of signs and symptoms of rheumatoid arthritis and OA.

HZNP SEC Filing Email Alerts Service

Open the HZNP Page at The Online Investor »

Company Name: 
Horizon Therapeutics Plc
Number of ETFs Holding HZNP: 
Total Market Value Held by ETFs: 
Total Market Capitalization: 
% of Market Cap. Held by ETFs: 

Open the HZNP Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes

Email EnvelopeFree HZNP Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Buy (2.55 out of 4)
6th percentile
(ranked lower than approx. 94% of all stocks covered)

Analysts' Target Price:
HZNP Stock Forecast

Based on Zacks ABR data;
powered by Xignite

Drugs & Pharmaceuticals M&A - Slide 24 of 100 Page |

Copyright © 1998 - 2023, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.